Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change $ Change
grade B $31.77 -0.03% -0.01
ACAD closed down 0.03 percent on Friday, January 13, 2017, on 72 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ACAD trend table...

Date Alert Name Type % Chg
Jan 13 200 DMA Support Bullish 0.00%
Jan 12 180 Bullish Setup Bullish Swing Setup -0.03%
Jan 12 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.03%
Jan 12 1,2,3 Pullback Bullish Bullish Swing Setup -0.03%
Jan 12 Bullish Engulfing Bullish -0.03%
Jan 12 Upside 200 DMA Break Bullish -0.03%
Jan 11 Downside 200 DMA Break Bearish 6.36%
Jan 10 Slingshot Bullish Bullish Swing Setup 0.95%
Jan 10 200 DMA Support Bullish 0.95%
Jan 9 Calm After Storm Range Contraction -2.81%

Older signals for ACAD ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.

Profile
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer’s disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson’s disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Is ACAD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 42.49
52 Week Low 16.64
Average Volume 2,674,578
200-Day Moving Average 31.31
50-Day Moving Average 27.89
20-Day Moving Average 29.43
10-Day Moving Average 31.15
Average True Range 1.72
ADX 29.62
+DI 27.94
-DI: 17.35
Chandelier Exit (Long, 3 ATRs) 28.17
Chandelier Exit (Short, 3 ATRs) 29.47
Upper Bollinger Band 33.84
Lower Bollinger Band 25.02
Percent B (%b) 0.77
Bandwidth 0.299694